Citigroup Inc. Sells 1,598 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Citigroup Inc. lowered its position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 39.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,459 shares of the medical instruments supplier’s stock after selling 1,598 shares during the period. Citigroup Inc.’s holdings in Mesa Laboratories were worth $258,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. MetLife Investment Management LLC increased its holdings in shares of Mesa Laboratories by 54.2% in the 1st quarter. MetLife Investment Management LLC now owns 2,668 shares of the medical instruments supplier’s stock worth $680,000 after purchasing an additional 938 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Mesa Laboratories by 0.7% during the first quarter. Rhumbline Advisers now owns 14,073 shares of the medical instruments supplier’s stock valued at $3,587,000 after buying an additional 93 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in Mesa Laboratories by 14.5% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,523 shares of the medical instruments supplier’s stock worth $1,153,000 after buying an additional 574 shares in the last quarter. BlackRock Inc. grew its stake in shares of Mesa Laboratories by 0.4% in the first quarter. BlackRock Inc. now owns 924,948 shares of the medical instruments supplier’s stock worth $235,751,000 after acquiring an additional 4,061 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Mesa Laboratories by 5.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 61,393 shares of the medical instruments supplier’s stock worth $15,648,000 after purchasing an additional 3,405 shares during the period. 90.60% of the stock is currently owned by hedge funds and other institutional investors.

Mesa Laboratories Price Performance

Shares of NASDAQ:MLAB opened at $107.25 on Thursday. The company has a market capitalization of $578.08 million, a P/E ratio of 630.92 and a beta of 0.83. Mesa Laboratories, Inc. has a 1-year low of $82.86 and a 1-year high of $187.75. The firm’s 50 day simple moving average is $101.03 and its two-hundred day simple moving average is $100.81. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.68 and a quick ratio of 1.86.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings data on Monday, February 5th. The medical instruments supplier reported $1.46 EPS for the quarter, missing the consensus estimate of $1.47 by ($0.01). The firm had revenue of $53.47 million for the quarter, compared to the consensus estimate of $54.90 million. Mesa Laboratories had a net margin of 0.45% and a return on equity of 7.41%. Research analysts expect that Mesa Laboratories, Inc. will post 6.15 EPS for the current fiscal year.

Mesa Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Thursday, February 29th were paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date of this dividend was Wednesday, February 28th. Mesa Laboratories’s dividend payout ratio (DPR) is 376.49%.

Analyst Ratings Changes

Separately, Evercore ISI upgraded Mesa Laboratories from an “in-line” rating to an “outperform” rating and upped their price target for the stock from $100.00 to $125.00 in a research report on Thursday, January 4th.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.